PTGX (Protagonist Therapeutics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTGX Protagonist Therapeutics Inc PTGX
53 GF Score
Price $143.54
GF Value $98.74
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.

PTGX
53GF Score
Protagonist Therapeutics Inc PTGX
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $143.54 is trading 45.4% above its estimated GF Value™ of $98.74. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • Short-term investments:
  • GF Value™: $98.74 vs. price of $143.54 (45.4% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
53GF Score

Get the complete analysis for PTGX

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$143.54
Price
$98.74
GF Value